Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Jones Lang LaSalle Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.09 (market cap $4.59B), while Jones Lang LaSalle Inc trades at $298.11 (market cap $13.95B). The key difference: Jones Lang LaSalle Inc is far larger — about 3× Definium Therapeutics Inc. Common Shares's market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Jones Lang LaSalle Inc for 71 Days on average.
| DFTX | JLL | |
|---|---|---|
Market Cap | $4.59B | $13.95B |
Volume | 2,103,937 | 457,462 |
Sector | Health | Real Estate |
52-Week High | $48.45 | $392.79 |
52-Week Low | $10.68 | $280.16 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $3.55B | $16.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JLL trades at $298.93, up 0.77% on the day, with a bearish technical signal but strong fundamental momentum. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue and net income have grown steadily, reaching $26.12B and $792.10M in 2025, respectively, while valuation ratios like a P/E of 14.54 and P/S of 0.53 appear attractive relative to historical norms.
The outlook is positive, supported by analyst consensus favoring a buy rating and a price target of $450.50, implying significant upside. Risks include exposure to real estate market cycles and competitive pressures, but JLL's expanding cash flow and strategic acquisitions in high-growth areas like data centers provide a solid foundation for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
